ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Association Between PD-L1/CD8 Expression and Outcomes in Melanoma Patients Who Received Dabrafenib/Trametinib

Dirk Schadendorf, MD
Published Online:1:21 PM, Wed July 19, 2017

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the association between PD-L1 and CD8 expression and outcomes in patients with BRAF V600E/K-mutant metastatic melanoma who received dabrafenib (Tafinlar) plus trametinib (Mekinist) in the randomized phase III COMBI-v study.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.